
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">FEBS Open Bio</journal-id><journal-id journal-id-type="iso-abbrev">FEBS Open Bio</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2211-5463</journal-id><journal-id journal-id-type="publisher-id">FEB4</journal-id><journal-title-group><journal-title>FEBS Open Bio</journal-title></journal-title-group><issn pub-type="epub">2211-5463</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6551500</article-id><article-id pub-id-type="doi">10.1002/2211-5463.12568</article-id><article-id pub-id-type="publisher-id">FEB412568</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Specific zinc finger‐induced methylation of PD‐L1 promoter inhibits its expression </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="left-running-head">X. Li <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="feb412568-cr-0001" contrib-type="author"><name><surname>Li</surname><given-names>Xue</given-names></name><xref ref-type="aff" rid="feb412568-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="feb412568-cr-0002" contrib-type="author"><name><surname>Wang</surname><given-names>Zhenni</given-names></name><xref ref-type="aff" rid="feb412568-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="feb412568-cr-0003" contrib-type="author"><name><surname>Huang</surname><given-names>Jiansheng</given-names></name><xref ref-type="aff" rid="feb412568-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="feb412568-cr-0004" contrib-type="author"><name><surname>Luo</surname><given-names>Huazao</given-names></name><xref ref-type="aff" rid="feb412568-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="feb412568-cr-0005" contrib-type="author"><name><surname>Zhu</surname><given-names>Sibo</given-names></name><xref ref-type="aff" rid="feb412568-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="feb412568-cr-0006" contrib-type="author"><name><surname>Yi</surname><given-names>Han</given-names></name><xref ref-type="aff" rid="feb412568-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="feb412568-cr-0007" contrib-type="author"><name><surname>Zheng</surname><given-names>Liuhai</given-names></name><xref ref-type="aff" rid="feb412568-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="feb412568-cr-0008" contrib-type="author"><name><surname>Hu</surname><given-names>Bo</given-names></name><xref ref-type="aff" rid="feb412568-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="feb412568-cr-0009" contrib-type="author"><name><surname>Yu</surname><given-names>Lili</given-names></name><xref ref-type="aff" rid="feb412568-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="feb412568-cr-0010" contrib-type="author"><name><surname>Li</surname><given-names>Lingzhi</given-names></name><xref ref-type="aff" rid="feb412568-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="feb412568-cr-0011" contrib-type="author" corresp="yes"><name><surname>Xie</surname><given-names>Jun</given-names></name><address><email>xiejun@fudan.edu.cn</email></address><xref ref-type="aff" rid="feb412568-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="feb412568-cr-0012" contrib-type="author" corresp="yes"><name><surname>Zhu</surname><given-names>Naishuo</given-names></name><address><email>nzhu@fudan.edu.cn</email></address><xref ref-type="aff" rid="feb412568-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="feb412568-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="feb412568-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Laboratory of Molecular Immunology</named-content>
<named-content content-type="organisation-division">State Key Laboratory of Genetic Engineering</named-content>
<named-content content-type="organisation-division">School of Life Sciences</named-content>
<named-content content-type="organisation-division">Institute of Biomedical Sciences</named-content>
<institution>Fudan University</institution>
<named-content content-type="city">Shanghai</named-content>
<country country="CN">China</country>
</aff><aff id="feb412568-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Institutes of Biomedical Science</named-content>
<institution>Fudan University</institution>
<named-content content-type="city">Shanghai</named-content>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
N. Zhu, Laboratory of Molecular Immunology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Institute of Biomedical Sciences, Fudan University, Shanghai 200438, China<break/>
Fax: +86 021 65641215<break/>
Tel: +86 021 65641215<break/>
E‐mail: <email>nzhu@fudan.edu.cn</email><break/>
and<break/>
J. Xie, Laboratory of Molecular Immunology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200438, China<break/>
E‐mail: <email>xiejun@fudan.edu.cn</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>5</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2019</year></pub-date><volume>9</volume><issue>6</issue><issue-id pub-id-type="doi">10.1002/feb4.2019.9.issue-6</issue-id><fpage>1063</fpage><lpage>1070</lpage><history><date date-type="received"><day>20</day><month>10</month><year>2017</year></date><date date-type="rev-recd"><day>31</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement content-type="article-copyright">© 2018 The Authors. Published by FEBS Press and John Wiley &amp; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:FEB4-9-1063.pdf"/><abstract id="feb412568-abs-0001"><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>DNA methylation of promoter regions is often associated with epigenetic silencing of gene expression, and DNA methyltransferase (DNMTs) has been used to suppress gene expression. </plain></SENT>
<SENT sid="2" pm="."><plain>In order to explore the synergistic roles of two methyltransferase members Dnmt3a and Dnmt1, we constructed expression plasmid that could express a recombinant DNMTs consisting of the C‐terminal domains of both Dnmt3a and Dnmt1 fused to a zinc finger domain which binds to the PD‐L1 promoter of human prostate cancer cells (DU145). </plain></SENT>
<SENT sid="3" pm="."><plain>Programmed death ligand 1 (PD‐L1, B7‐H1, CD‐274) is a transmembrane protein widely expressed on antigen‐presenting and other immune cells. </plain></SENT>
<SENT sid="4" pm="."><plain>The interaction of PD‐L1 with its receptor PD‐1 is considered an ‘immune checkpoint' for possible cancer therapy. </plain></SENT>
<SENT sid="5" pm="."><plain>DU145 cells treated with the Dnmt3aC‐1C plasmid showed significantly reduced expression of PD‐L1 as compared to Dnmt3aC or Dnmt1C alone. </plain></SENT>
<SENT sid="6" pm="."><plain>Our results show that the fusion of Dnmt1 improves the methylation activity of Dnmt3a and enhances its biological functions. </plain></SENT>
<SENT sid="7" pm="."><plain>This combinatorial strategy can be used to better control PD‐L1 expression to support cytotoxic T lymphocytes (CTL) response against tumors. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group kwd-group-type="author-generated"><kwd id="feb412568-kwd-0001">DNA methylation</kwd><kwd id="feb412568-kwd-0002">PD‐L1</kwd><kwd id="feb412568-kwd-0003">tumor</kwd><kwd id="feb412568-kwd-0004">zinc finger</kwd></kwd-group></SecTag><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>31370927</award-id><award-id>30571650</award-id></award-group><award-group><funding-source>National Major Scientific and Technological Special Project</funding-source><award-id>2012ZX10002006‐002‐003</award-id></award-group><award-group><funding-source>Natural Science Foundation of Zhejiang Province (CN)</funding-source><award-id>LY18H160059</award-id></award-group><award-group><funding-source>Natural Science Foundation of Shanghai</funding-source><award-id>13431900602</award-id></award-group></funding-group><counts><fig-count count="4"/><table-count count="1"/><page-count count="8"/><word-count count="3705"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>feb412568</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2019</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.5 mode:remove_FC converted:28.06.2019</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="feb412568-ntgp-0001"><fn id="feb412568-note-1008"><p><text><SENT sid="8" pm="."><plain>Xue Li and Zhenni Wang contributed equally to this work. </plain></SENT>
</text></p></fn></fn-group></notes></front><body><def-list list-content="abbreviations" id="feb412568-dl-0001"><title><text><SENT sid="9" pm="."><plain>Abbreviations </plain></SENT>
</text></title><def-item><term>CTL</term><def><p><text><SENT sid="10" pm="."><plain>cytotoxic T lymphocytes </plain></SENT>
</text></p></def></def-item><def-item><term>DNMTs</term><def><p><text><SENT sid="11" pm="."><plain>DNA methyltransferase </plain></SENT>
</text></p></def></def-item><def-item><term>MSP</term><def><p><text><SENT sid="12" pm="."><plain>methylation‐specific PCR </plain></SENT>
</text></p></def></def-item></def-list><p><text><SENT sid="13" pm="."><plain>Programmed cell death ligand 1 (PD‐L1, B7‐H1, CD274) is a transmembrane protein that is widely expressed on antigen‐presenting and other immune cells, and is unregulated on tumor cells from a broad range of cancer types. </plain></SENT>
<SENT sid="14" pm="."><plain>Binding of PD‐L1 with its receptor PD‐1 on T cells delivers a signal that inhibits TCR‐mediated activation of IL‐2 production and T‐cell proliferation. </plain></SENT>
<SENT sid="15" pm="."><plain>PD‐L1 binding to PD‐1 also contributes to ligand‐induced TCR downregulation during antigen presentation to naive T cells 1. </plain></SENT>
<SENT sid="16" pm="."><plain>In addition, the PD‐1/PD‐L1 interaction is also implicated in autoimmunity 2, 3. </plain></SENT>
</text></p><p><text><SENT sid="17" pm="."><plain>Using a PD‐L1 inhibitor that blocks the interaction of PD‐L1 with the PD‐1 receptor can prevent cancer from evading host immune system. </plain></SENT>
<SENT sid="18" pm="."><plain>So, blocking the PD‐1/PD‐L1 interaction can suppress tumor immune escape, thereby improving the ability of initial T‐cell activation and CTL killing activity 4. </plain></SENT>
<SENT sid="19" pm="."><plain>Several PD‐L1 inhibitor antibodies are being trialed for use in advanced melanoma, non‐small‐cell lung cancer, renal cell carcinoma, and bladder cancer 5. </plain></SENT>
<SENT sid="20" pm="."><plain>Immunotherapy with these immune checkpoint inhibitors appears to shrink tumors in a greater number of patients across a wider range of tumor types. Hence, PD‐L1 inhibitors are considered to be the most promising drug category for many different cancers 6. </plain></SENT>
<SENT sid="21" pm="."><plain>However, the large size of the antibody limits its ability to properly penetrate solid tumors in order for it to act. </plain></SENT>
<SENT sid="22" pm="."><plain>Shrinking the tumor with other treatment modalities before using immune checkpoint immunotherapy could avoid this 7, 8. </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>DNA methylation of promoter regions is often associated with epigenetic silencing 9. </plain></SENT>
<SENT sid="24" pm="."><plain>In normal tissue, around 80% of CpGs are methylated whereas CpG islands in promoter regions of active genes are hypomethylated 10. </plain></SENT>
<SENT sid="25" pm="."><plain>In cancer, there is a shift in the pattern of DNA methylation toward a global hypomethylation, whereas certain CpGs, often in promoter regions of tumor suppressor genes, are thought to become hypermethylated 10, 11. </plain></SENT>
<SENT sid="26" pm="."><plain>Nevertheless, recent publications show that the aberrant DNA methylation, especially in cancer, is much more complex 9. </plain></SENT>
<SENT sid="27" pm="."><plain>Methylation in promoter regions correlates negatively with gene expression and makes important genes such as tumor suppressor genes, DNA repair, and other genes lose their functions 12. </plain></SENT>
</text></p><p><text><SENT sid="28" pm="."><plain>The DNA methyltransferase (DNMTs) comprises a family of DNA‐modifying enzymes that have a central role in epigenetic gene regulation. </plain></SENT>
<SENT sid="29" pm="."><plain>Global cytosine methylation patterns in mammals appear to be established by a complex interplay of at least three independently encoded DNMTs: DNMT1, DNMT3A, and DNMT3B 13. </plain></SENT>
<SENT sid="30" pm="."><plain>The primary function of Dnmt1 is the maintenance of the DNA methylation pattern during replication, whereas Dnmt3a and Dnmt3b function as de novo methyltransferases 14. </plain></SENT>
<SENT sid="31" pm="."><plain>The human DNMTs 1, 3A, and 3B coordinate mRNA expression in normal tissues and overexpression in tumors. </plain></SENT>
<SENT sid="32" pm="."><plain>The expression levels of these DNMTs are reportedly elevated in cancers of the colon, prostate, breast, liver, and in leukemia. </plain></SENT>
<SENT sid="33" pm="."><plain>Conversely, reduction in DNMT1 levels appears to have protective effects 15. </plain></SENT>
</text></p><p><text><SENT sid="34" pm="."><plain>DNA methyltransferases have been used to repress target gene through specific DNA methylation, with guidance to the promoter region of a target gene by fusing it to a specific zinc finger domain 16 . </plain></SENT>
<SENT sid="35" pm="."><plain>In this study, we explored the synergistic methylation activities of Dnmt3a and Dnmt1 on PD‐L1 gene promoter. </plain></SENT>
<SENT sid="36" pm="."><plain>We used a recombinant Ad‐ZF‐Dnmt3aC‐1C expression construct to inhibit the expression of PD‐L1 and thus prevent PD‐1/PD‐L1 interaction. </plain></SENT>
<SENT sid="37" pm="."><plain>This construct expresses a fusion protein that consists of the C‐terminal domains of both Dnmt3a and Dnmt1 fused with a zinc finger domain that could specifically bind to PD‐L1 promoter. </plain></SENT>
<SENT sid="38" pm="."><plain>Human prostate cancer cells (DU145) treated with Ad‐ZF‐Dnmt3aC‐1C showed significant reduction in PD‐L1 expression as compared to Ad‐ZF‐Dnmt3aC or Ad‐ZF‐Dnmt1C alone. </plain></SENT>
<SENT sid="39" pm="."><plain>Our results show that the fusion of Dnmt1C strengthens the biological functions of Dnmt3a. </plain></SENT>
<SENT sid="40" pm="."><plain>This strategy can be used to target genes of interest more efficiently, for example, to block PD‐1/PD‐L1 interaction thereby augmenting CTL activity for killing tumors. </plain></SENT>
</text></p><SecTag type="METHODS"><sec id="feb412568-sec-0003"><title><text><SENT sid="41" pm="."><plain>Materials and methods </plain></SENT>
</text></title><sec id="feb412568-sec-0004"><title><text><SENT sid="42" pm="."><plain>Study design </plain></SENT>
</text></title><p><text><SENT sid="43" pm="."><plain>We used Eukaryotic Gene Promoter Database to analyze PD‐L1 gene promoter sequence. </plain></SENT>
<SENT sid="44" pm="."><plain>CpG Island Analysis Software (<ext-link ext-link-type="uri" xlink:href="http://www.urogene.org/methprimer">http://www.urogene.org/methprimer</ext-link>) was used to analyze the core promoter sequences of potential methylation site (CpG island), and zinc finger protein binding site on PD‐L1 gene promoter was identified by the software (<ext-link ext-link-type="uri" xlink:href="http://www.scripps.edu/barbas/zfdesign/register.php?query">http://www.scripps.edu/barbas/zfdesign/register.php?query</ext-link>). </plain></SENT>
<SENT sid="45" pm="."><plain>Putative methylation and zinc finger protein binding sites on PD‐L1 promoter are shown in Fig. 1A. </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="feb412568-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="46" pm="."><plain>Zinc finger‐fused recombinant Dnmts vectors. </plain></SENT>
<SENT sid="47" pm="."><plain>(A) Putative methylation and zinc finger protein binding sites of PD‐L1 promoter. </plain></SENT>
<SENT sid="48" pm="."><plain>The second strand represents the sequence of the bisulfite converted methylated DNA (B) Schematic representation of zinc finger‐fused Dnmts vectors. </plain></SENT>
<SENT sid="49" pm="."><plain>(C) PD‐L1 ZF interaction model. </plain></SENT>
<SENT sid="50" pm="."><plain>The model is based on a crystal structure of zinc finger protein (PDB: <ext-link ext-link-type="pdb" xlink:href="2I13">2I13</ext-link>). </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-3" xlink:href="FEB4-9-1063-g001"/></fig></sec><sec id="feb412568-sec-0005"><title><text><SENT sid="51" pm="."><plain>Recombinant adenovirus vector constructs </plain></SENT>
</text></title><p><text><SENT sid="52" pm="."><plain>All the zinc finger‐fused Dnmts sequences were commercially inserted into replication‐deficient adenoviral vectors pDOV‐mCMV‐GFP‐3FLAG (Obio Technology, Shanghai, China) by Neuron Biotech, Shanghai, China, and abbreviated as Ad‐ZF‐Dnmt3aC‐1C. </plain></SENT>
</text></p><p><text><SENT sid="53" pm="."><plain>The C terminus of Dnmt3a (2217–3074; GenBank: <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NM_175629.1">NM_175629.1</ext-link>) and Dnmt1 (3270–5028; GenBank: <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NM_001379.2">NM_001379.2</ext-link>) were generated from pcDNA3.1/Flag‐Dnmt3a and pcDNA3.1/Flag‐Dnmt1 by PCR using primers listed in Table 1. </plain></SENT>
<SENT sid="54" pm="."><plain>The Dnmt1C fragment was fused to the C terminus of Dnmt3aC (pZF‐Dnmt3aC) with a flexible linker (Gly4Ser)2 to generate pZF‐Dnmt3aC‐1C and this to the C terminus of zinc finger (ZF). </plain></SENT>
<SENT sid="55" pm="."><plain>These recombinant Dnmt constructs were commercially packed into replication‐defective adenoviral vector pDOV‐mCMV‐GFP‐3FLAG (Neuron Biotech) to generate Ad‐ZF‐Dnmt3aC‐1C. </plain></SENT>
<SENT sid="56" pm="."><plain>The pDOV‐mCMV‐GFP‐3FLAG was considered as negative control (Ad‐control). </plain></SENT>
<SENT sid="57" pm="."><plain>The resulting vectors are schematically represented in Fig. 1B. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="feb412568-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="58" pm="."><plain>List of primers </plain></SENT>
</text></p></caption><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap></SecTag></sec><sec id="feb412568-sec-0006"><title><text><SENT sid="59" pm="."><plain>Cell culture and cells transduction </plain></SENT>
</text></title><p><text><SENT sid="60" pm="."><plain>Human prostate cancer cells (DU145) were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). </plain></SENT>
<SENT sid="61" pm="."><plain>Cells were cultured in standard DMEM with 10% fetal bovine serum, 1% penicillin/streptomycin at 37 °C, and 5% CO2. </plain></SENT>
<SENT sid="62" pm="."><plain>For transduction, 2.0 × 105 cells were cultured in 12‐well plates in regular growth medium until they reached 70–80% confluency. </plain></SENT>
<SENT sid="63" pm="."><plain>Cells were infected with Dnmts vectors at 80–100 MOIs (multiplicity of infection) per cell. </plain></SENT>
</text></p></sec><sec id="feb412568-sec-0007"><title><text><SENT sid="64" pm="."><plain>Western blot analysis </plain></SENT>
</text></title><p><text><SENT sid="65" pm="."><plain>Total proteins were collected from the infected cells after 24, 48, and 72 h, run on 10% SDS/PAGE, and detected with 3000× diluted anti‐PD‐L1 monoclonal antibody (Clone EPR1161, Abcam, Cambridge, UK) overnight. </plain></SENT>
<SENT sid="66" pm="."><plain>The antibody was removed, and the poly(vinylidene difluoride) membrane was washed three times for 5 min each in TBST. </plain></SENT>
<SENT sid="67" pm="."><plain>Anti‐rabbit secondary antibody (Abcam) was used at a dilution of 1 : 5000 in TBST and incubated for 1 h at room temperature. </plain></SENT>
<SENT sid="68" pm="."><plain>The antigen–antibody complexes were detected using the G:BOX F3 gel doc system (Syngene, Cambridge, UK). </plain></SENT>
</text></p></sec><sec id="feb412568-sec-0008"><title><text><SENT sid="69" pm="."><plain>Flow cytometry </plain></SENT>
</text></title><p><text><SENT sid="70" pm="."><plain>Cells were cultured in 6‐well plates in regular growth media until they reached 70–80% confluency. </plain></SENT>
<SENT sid="71" pm="."><plain>Cells were fixed with 4% PFA and washed. </plain></SENT>
<SENT sid="72" pm="."><plain>PD‐L1 was detected using PE‐conjugated anti‐PD‐L1 antibody (BD Biosciences, Franklin Lakes, NJ, USA) on Calibur flow cytometer (BD Bioscience), and data were analyzed using flowjo software (Tree Star, San Carlos, CA, USA). </plain></SENT>
</text></p></sec><sec id="feb412568-sec-0009"><title><text><SENT sid="73" pm="."><plain>RNA preparation and quantitative real‐time PCR (qRT–PCR) </plain></SENT>
</text></title><p><text><SENT sid="74" pm="."><plain>Total RNA from treated and control cells were isolated after 24, 48, and 72 h using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. </plain></SENT>
<SENT sid="75" pm="."><plain>For each sample, 2 μg of total RNA was reversely transcribed using the QuantiTect Reverse Transcription Kit (Qiagen Inc., Valencia, CA, USA). </plain></SENT>
<SENT sid="76" pm="."><plain>Gene expression was determined using the DyNAmo Flash SYBR Green qPCR Kit (Thermo Scientific Inc., Foster, CA, USA) on the Stratagene Thermocycler (Mx3000). </plain></SENT>
<SENT sid="77" pm="."><plain>The primers used are listed in Table 1. </plain></SENT>
</text></p></sec><sec id="feb412568-sec-0010"><title><text><SENT sid="78" pm="."><plain>Methylation‐specific PCR (MSP) assay and DNA extraction </plain></SENT>
</text></title><p><text><SENT sid="79" pm="."><plain>To check the degree of methylation of PD‐L1 promoter, methylation‐specific PCR (MSP) was performed as described earlier 13. </plain></SENT>
<SENT sid="80" pm="."><plain>DU145 cells were cotransfected with plasmid Ad‐ZF‐Dnmt3aC, Ad‐ZF‐Dnmt1C, Ad‐ZF‐Dnmt3aC‐1C, or pDOV‐mCMV‐GFP‐3FLAG (Ad‐control) for 40 h. </plain></SENT>
<SENT sid="81" pm="."><plain>The promoter of interleukin‐4 receptor (IL‐4R) was also analyzed as off‐target control 14. </plain></SENT>
<SENT sid="82" pm="."><plain>Bisulfite reaction was performed on 500 ng of DNA. </plain></SENT>
<SENT sid="83" pm="."><plain>Sodium bisulfite conversion and purification of DNA were performed with the EpiTech Plus Bisulfite Conversion Kit (Qiagen, Hilden, Germany). </plain></SENT>
<SENT sid="84" pm="."><plain>Cell genomes were extracted, and a fragment corresponding to the PD‐L1 promoter sequence was amplified with primers designed with the methprimer software (Beijing, China) for methylated DNA (Table 1). </plain></SENT>
<SENT sid="85" pm="."><plain>The amplified fragment was cloned into the pMD19‐T vector and sequenced. </plain></SENT>
<SENT sid="86" pm="."><plain>Data analysis and data quality check were carried out using the biq analyzer software, a standard tool for processing DNA methylation data from bisulfite sequencing (<ext-link ext-link-type="uri" xlink:href="http://biqanalyzer.bioinf.mpi-inf.mpg.de/">http://biqanalyzer.bioinf.mpi-inf.mpg.de/</ext-link>). </plain></SENT>
</text></p></sec><sec id="feb412568-sec-0011"><title><text><SENT sid="87" pm="."><plain>Statistical analyses </plain></SENT>
</text></title><p><text><SENT sid="88" pm="."><plain>Statistical tests were performed with the spss software (SPSS Inc., Chicago, IL, USA). </plain></SENT>
<SENT sid="89" pm="."><plain>The data are reported as means ± SD. </plain></SENT>
<SENT sid="90" pm="."><plain>Different experimental groups were compared by Student's t‐test. </plain></SENT>
<SENT sid="91" pm="."><plain>A value of P &lt; 0.05 was considered statistically significant. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="feb412568-sec-0012"><title><text><SENT sid="92" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="93" pm="."><plain>Analysis with Eukaryotic Gene Promoter Database showed that PD‐L1 gene promoter sequence is highly methylated in normal cells and is hypomethylated in tumor cells. </plain></SENT>
<SENT sid="94" pm="."><plain>Using Tools Ver3.0 design software, we identified PD‐L1 gene promoter and GC box including downstream GTCCGCCTGCAGGTAGGGAGC zinc finger binding site. </plain></SENT>
<SENT sid="95" pm="."><plain>The 100‐bp‐long fragment contained 15 potential methylation sites, of which three were located in GC box (Fig. 1A). </plain></SENT>
</text></p><sec id="feb412568-sec-0013"><title><text><SENT sid="96" pm="."><plain>Recombinant Dnmts protein expression </plain></SENT>
</text></title><p><text><SENT sid="97" pm="."><plain>To study the expression of ZF‐Dnmts from Ad‐ZF‐Dnmt vectors, T293 cells were infected with Ad‐ZF‐Dnmts or Ad‐control. </plain></SENT>
<SENT sid="98" pm="."><plain>The recombinant ZF‐Dnmt3aC, Ad‐ZF‐Dnmt1C, and ZF‐Dnmt3aC‐1C were successfully expressed in T293 cells as shown in Fig. 2. </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="feb412568-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p><text><SENT sid="99" pm="."><plain>Expression of recombinant ZF‐Dnmt protein. </plain></SENT>
<SENT sid="100" pm="."><plain>(A,B) T293 cells were infected with ZF‐Dnmt1C, ZFDnmt3aC, ZF‐Dnmt3a‐1C or Ad‐control, and the expression of recombinant proteins was checked at 48 h. </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-5" xlink:href="FEB4-9-1063-g002"/></fig></sec><sec id="feb412568-sec-0014"><title><text><SENT sid="101" pm="."><plain>Recombinant ZF‐Dnmt3aC‐1C suppresses PD‐L1 expression more efficiently </plain></SENT>
</text></title><p><text><SENT sid="102" pm="."><plain>Human prostate cancer cells (DU145) were transduced with Ad‐ZF‐Dnmt3aC, Ad‐ZF‐Dnmt3aC‐1C, or Ad‐control, and the expression of PD‐L1 was checked at 24, 48, and 72 h. </plain></SENT>
<SENT sid="103" pm="."><plain>Western blot analysis showed that ZF‐Dnmt3aC‐1C suppressed the expression of PD‐L1 more efficiently as compared to ZF‐Dnmt3aC alone and the expression level was reduced to less than half after 72 h as shown in Fig. 3A. </plain></SENT>
<SENT sid="104" pm="."><plain>This was further authenticated by flow cytometry results. </plain></SENT>
<SENT sid="105" pm="."><plain>Flow cytometry analysis showed that as compared to the mock (53.1%) and Ad‐control group (49.2%), ZF‐Dnmt3aC‐1C suppressed the expression of PD‐L1 to 19.28% (Fig. 3B). </plain></SENT>
<SENT sid="106" pm="."><plain>These results were further confirmed at the level of mRNA expression as assessed by qRT–PCR at the different time intervals showing that the expression of PD‐L1 was reduced by 50–60% by ZF‐Dnmt3aC‐1C (Fig. 3C). </plain></SENT>
<SENT sid="107" pm="."><plain>These results show that the addition of Dnmt1C to the Dnmt3aC improves its biological activity of methylation and hence suppresses the expression of PD‐L1 more efficiently. </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="feb412568-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p><text><SENT sid="108" pm="."><plain>Effect of ZF‐Dnmt3aC‐1C on the expression of PD‐L1. </plain></SENT>
<SENT sid="109" pm="."><plain>Human prostate cancer cells (DU145) were transduced with Ad‐ZF‐Dnmts or Ad‐control, and the expression of PD‐L1 was checked at 24, 48, and 72 h. </plain></SENT>
<SENT sid="110" pm="."><plain>(A) Western blot analysis, (B) flow cytometry, (C) qRT–PCR. </plain></SENT>
<SENT sid="111" pm="."><plain>Error bars represent ± SD.(*P &lt; 0.05, **P &lt; 0.01). </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-7" xlink:href="FEB4-9-1063-g003"/></fig></sec><sec id="feb412568-sec-0015"><title><text><SENT sid="112" pm="."><plain>Degree of methylation by Methylation‐Specific PCR (MSP) assay </plain></SENT>
</text></title><p><text><SENT sid="113" pm="."><plain>Methylation‐specific PCR assay was performed 72 h after transfection of DU145 cells with Ad‐control or Ad‐ZF‐Dnmts. </plain></SENT>
<SENT sid="114" pm="."><plain>The result showed lower methylation for mock (16%) and control group (18.7%) than the experimental groups. </plain></SENT>
<SENT sid="115" pm="."><plain>The Ad‐ZF‐Dnmt3aC showed 25.7%, Ad‐ZF‐Dnmt1C showed 35.3%, and Ad‐ZF‐Dnmt3aC‐1C group showed highest methylation reaching 84%. (Fig. 4). </plain></SENT>
<SENT sid="116" pm="."><plain>These results further support the idea that fusion of Dnmt1C to the Dnmt3aC improves its biological activity of methylation. </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="feb412568-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p><text><SENT sid="117" pm="."><plain>Methylation‐specific PCR assay: MSP assay was performed 72 h after cotransfection of DU145 with Ad‐control and Ad‐ZF‐Dnmts. </plain></SENT>
<SENT sid="118" pm="."><plain>Error bars represent ± SD.(**P &lt; 0.01) . </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-9" xlink:href="FEB4-9-1063-g004"/></fig></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="feb412568-sec-0016"><title><text><SENT sid="119" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="120" pm="."><plain>Targeting the DNA methylation‐based gene‐silencing machinery has assumed great significance in the field of cancer epigenomics 15.We applied this idea to the suppression of PD‐L1 gene expression to block PD‐1/PD‐L1 interaction. </plain></SENT>
<SENT sid="121" pm="."><plain>First, we identified the potential methylation sites and zinc finger binding site in the promoter region of PD‐L1 gene. </plain></SENT>
<SENT sid="122" pm="."><plain>Then, we constructed recombinant plasmids consisting of the C‐terminal domains of both Dnmt1 and Dnmt3a methyltransferases fused to a zinc finger domain that specifically bind to PD‐L1 promoter of prostate cancer cell line DU145. </plain></SENT>
<SENT sid="123" pm="."><plain>Methylation‐specific PCR showed that the designed constructs have successfully methylated the promoter sequences in the experimental group. </plain></SENT>
<SENT sid="124" pm="."><plain>Further results showed that treatment of DU145 cells with this protein significantly reduced the expression of PD‐L1 as evaluated at antibody‐specific western blot. </plain></SENT>
<SENT sid="125" pm="."><plain>This was further supported by the result of flow cytometry, which showed that mock and control group is 53.1% and 49.2%, respectively, while the experimental group decreased to 19.28%. </plain></SENT>
<SENT sid="126" pm="."><plain>However, the mock group which was treated with the empty vectors did not show such reduction in the expression of PD‐L1 level. </plain></SENT>
<SENT sid="127" pm="."><plain>As a whole, the promoter sequence of PD‐L1 was methylated which suppressed the expression level of PD‐L1. </plain></SENT>
</text></p><p><text><SENT sid="128" pm="."><plain>Gevensleben et al. reported that there is an inverse correlation between PD‐L1 promoter methylation and protein expression in prostate cancer. </plain></SENT>
<SENT sid="129" pm="."><plain>They suggest that PD‐L1 is inversely correlated with miR as cellular component, which modifies the downstream processing of PD‐L1 mRNA. </plain></SENT>
<SENT sid="130" pm="."><plain>Differential expression of miR may therefore potentially interfere with the linear translation of PD‐L1 mRNA into PD‐L1 protein 16. </plain></SENT>
<SENT sid="131" pm="."><plain>D. </plain></SENT>
<SENT sid="132" pm="."><plain>Goltz et al. also report on the inverse correlation between promoter methylation and respective mRNA expression 17, 18. </plain></SENT>
<SENT sid="133" pm="."><plain>These studies support our results of suppression of PD‐L1 by methylating its promoter. </plain></SENT>
</text></p><p><text><SENT sid="134" pm="."><plain>Further we evaluated the cooperative role of different Dnmts with respect to DNA methylation and subsequent PD‐L1 expression. </plain></SENT>
<SENT sid="135" pm="."><plain>The specific roles of these Dnmts in de novo and maintenance functions have recently been re‐examined. </plain></SENT>
<SENT sid="136" pm="."><plain>Although single knockout of either Dnmt1 or Dnmt3b gene had minimal effects on DNA demethylation in colon cancer cells, 19 knockouts of both Dnmt1 and Dnmt3b genes led to demethylation and re‐expression of tumor suppressor genes in these cells 20. </plain></SENT>
<SENT sid="137" pm="."><plain>This observation implies that Dnmt1 and Dnmt3b together cooperate to maintain DNA methylation patterns and to silence genes in human cancer cells. </plain></SENT>
<SENT sid="138" pm="."><plain>In separate knockdown studies using RNA interference techniques, double RNA interference of Dnmt1 plus Dnmt3b enhanced DNA demethylation and gene reactivation 21. </plain></SENT>
<SENT sid="139" pm="."><plain>El‐Osta reported that the methyltransferases Dnmt1 and Dnmt3b cooperatively maintain DNA methylation and gene silencing in human cancer cells. </plain></SENT>
<SENT sid="140" pm="."><plain>Disruption of the human Dnmt3b only slightly reduces the overall global DNA methylation; however, demethylation was markedly potentiated when both Dnmt1 and Dnmt3b were simultaneously deleted 22. </plain></SENT>
<SENT sid="141" pm="."><plain>Based on this, we hypothesized that the cooperative role of Dnmt3a and Dnmt1 might augment the biological function of Dnmt3a. </plain></SENT>
<SENT sid="142" pm="."><plain>We fused the C‐terminal of Dnmt1 (Dnmt1C) to the Dnmmt3aC and evaluated the expression of PD‐L1. </plain></SENT>
<SENT sid="143" pm="."><plain>Our results showed that the addition of Dnmt1C to Dnmt3aC synergize its biological function and improved its methylation efficiency. </plain></SENT>
<SENT sid="144" pm="."><plain>Thus Dnmt3aC‐1C suppressed PD‐L1 expression more efficiently as compared to Dnnmt3ac alone. </plain></SENT>
<SENT sid="145" pm="."><plain>This concept of combining Dnmts can be extended to suppress other genes. </plain></SENT>
</text></p></sec></SecTag><SecTag type="COMP_INT"><sec sec-type="COI-statement" id="feb412568-sec-0018"><title><text><SENT sid="146" pm="."><plain>Conflict of interest </plain></SENT>
</text></title><p><text><SENT sid="147" pm="."><plain>The authors declare no conflict of interest. </plain></SENT>
</text></p></sec></SecTag><SecTag type="AUTH_CONT"><sec id="feb412568-sec-0019"><title><text><SENT sid="148" pm="."><plain>Author contributions </plain></SENT>
</text></title><p><text><SENT sid="149" pm="."><plain>NZ, JH, XL, and ZW conceived and designed the project. </plain></SENT>
<SENT sid="150" pm="."><plain>XL and ZW performed the experimental work. </plain></SENT>
<SENT sid="151" pm="."><plain>XL wrote the manuscript, researched the data, reviewed and edited the manuscript. </plain></SENT>
<SENT sid="152" pm="."><plain>JX, HL, SZ, HY, LZ, BH, LY, and LL contributed to the discussion. </plain></SENT>
<SENT sid="153" pm="."><plain>Funding acquisition by NZ. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack id="feb412568-sec-0017"><title>Acknowledgements</title><p><text4fund><text><SENT sid="154" pm="."><plain>This work was supported by National Major Scientific and Technological Special Project (2012ZX10002006‐002‐003), National Natural Science Foundation of China (31370927 and 30571650), Natural Science Foundation of Zhejiang Province (CN) (LY18H160059), and Natural Science Foundation of Shanghai (13431900602). </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list content-type="cited-references" id="feb412568-bibl-0001"><title>References</title><ref id="feb412568-bib-0001"><text><SENT sid="155" pm="."><plain>1  Karwacz K ,  Bricogne C ,  MacDonald D ,  Arce F ,  Bennett CL ,  Collins M  and  Escors D  (2011) PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8 +  T cells. EMBO Mol Med 3, 581–592.21739608 </plain></SENT>
</text></ref><ref id="feb412568-bib-0002"><text><SENT sid="156" pm="."><plain>2  Ansari MJI ,  Salama AD ,  Chitnis T ,  Smith RN ,  Yagita H ,  Akiba H ,  Yamazaki T ,  Azuma M ,  Iwai H ,  Khoury SJ  et al (2003) The programmed death‐1 (PD‐1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198, 63–69.12847137 </plain></SENT>
</text></ref><ref id="feb412568-bib-0003"><text><SENT sid="157" pm="."><plain>3  Mozaffarian N ,  Wiedeman AE  and  Stevens AM  (2008) Active systemic lupus erythematosus is associated with failure of antigen‐presenting cells to express programmed death ligand‐1. Rheumatology (Oxford) 47, 1335–1341.18650228 </plain></SENT>
</text></ref><ref id="feb412568-bib-0004"><text><SENT sid="158" pm="."><plain>4  Thompson RH ,  Dong H ,  Lohse CM ,  Leibovich BC ,  Blute ML ,  Cheville JC  and  Kwon ED  (2007) PD‐1 is expressed by tumor‐infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 13, 1757–1761.17363529 </plain></SENT>
</text></ref><ref id="feb412568-bib-0005"><text><SENT sid="159" pm="."><plain>5  Sunshine J  and  Taube JM  (2015) PD‐1/PD‐L1 inhibitors. Curr Opin Pharmacol 23, 32–38.26047524 </plain></SENT>
</text></ref><ref id="feb412568-bib-0006"><text><SENT sid="160" pm="."><plain>6  Guha M  (2014) Immune checkpoint inhibitors bring new hope to cancer patients. Phar J. </plain></SENT>
</text></ref><ref id="feb412568-bib-0007"><text><SENT sid="161" pm="."><plain>7  Tamaru H  and  Selker EV  (2001) A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 414, 277–283.11713521 </plain></SENT>
</text></ref><ref id="feb412568-bib-0008"><text><SENT sid="162" pm="."><plain>8  Gao Q ,  Wang XY ,  Qiu SJ ,  Yamato I ,  Sho M ,  Nakajima Y ,  Zhou J ,  Li BZ ,  Shi YH ,  Xiao YS  et al (2009) Over‐ expression of PD‐L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15, 971–979.19188168 </plain></SENT>
</text></ref><ref id="feb412568-bib-0009"><text><SENT sid="163" pm="."><plain>9  Jones PA  (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13, 484–492.22641018 </plain></SENT>
</text></ref><ref id="feb412568-bib-0010"><text><SENT sid="164" pm="."><plain>10  Eckhardt F ,  Lewin J ,  Cortese R ,  Rakyan VK ,  Attwood J ,  Burger M ,  Burton J ,  Cox TV ,  Davies R ,  Down TA  et al (2006) DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 38, 1378–1385.17072317 </plain></SENT>
</text></ref><ref id="feb412568-bib-0011"><text><SENT sid="165" pm="."><plain>11  Lee ST  and  Wiemels JL  (2016) Genome‐wide CpG island methylation and intergenic demethylation propensities vary among different tumor sites. Nucleic Acids Res 44, 1105–1117.26464434 </plain></SENT>
</text></ref><ref id="feb412568-bib-0012"><text><SENT sid="166" pm="."><plain>12  Rhee I ,  Bachman KE  and  Park BH  (2002) Dnmt1 and Dnmt 3b cooperate to silence genes in human cancer cells. Nature 416, 552–556.11932749 </plain></SENT>
</text></ref><ref id="feb412568-bib-0013"><text><SENT sid="167" pm="."><plain>13 The DNA methyltransferase family (2018) A versatile toolkit for epigenetic regulation. Nat Rev Genet 19, 81–92.29033456 </plain></SENT>
</text></ref><ref id="feb412568-bib-0014"><text><SENT sid="168" pm="."><plain>14  Chen T  and  Li E  (2004) Structure and function of eukaryotic DNA methyltransferases. Curr Top Dev Biol 60, 55–89.15094296 </plain></SENT>
</text></ref><ref id="feb412568-bib-0015"><text><SENT sid="169" pm="."><plain>15  Subramaniam D ,  Thombre R ,  Dhar A  and  Anant S  (2014) DNA methyltransferases: a novel target for prevention and therapy. Front Oncol 4, 80.24822169 </plain></SENT>
</text></ref><ref id="feb412568-bib-0016"><text><SENT sid="170" pm="."><plain>16  Li F ,  Papworth M ,  Minczuk M ,  Rohde C ,  Zhang Y ,  Ragozin S  and  Jeltsch A  (2007) Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes. Nucleic Acids Res 35, 100–112. 10.1093/nar/gkl1035.17151075 </plain></SENT>
</text></ref><ref id="feb412568-bib-0017"><text><SENT sid="171" pm="."><plain>17  Herman JG ,  Graff JR ,  Myohanen S ,  Nelkin BD  and  Baylin SB  (1996) Methylation‐specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci 93, 9821–9826.8790415 </plain></SENT>
</text></ref><ref id="feb412568-bib-0018"><text><SENT sid="172" pm="."><plain>18  Xirong L ,  Rui L ,  Xiaoli Y ,  Qiuyan H ,  Bikui T ,  Sibo Z  and  Naishuo Z  (2014) Hepatitis B Virus can be inhibited by DNA methyltransferase 3a via specific zinc‐finger‐induced methylation of the X promoter. Biochemistry (Mosc) 79, 111–123.24794726 </plain></SENT>
</text></ref><ref id="feb412568-bib-0019"><text><SENT sid="173" pm="."><plain>19  Kar S ,  Sengupta D ,  Deb M ,  Shilpi S ,  Parbin S ,  Rath SK ,  Pradhan N ,  Rakshit M  and  Patra SK  (2014) Expression profiling of DNA methylation‐mediated epigenetic gene‐silencing factors in breast cancer. Clin Epigenetics 6, 20.25478034 </plain></SENT>
</text></ref><ref id="feb412568-bib-0020"><text><SENT sid="174" pm="."><plain>20  Gevensleben H ,  Holmes EE ,  Goltz D ,  Dietrich J ,  Sailer V ,  Ellinger J ,  Dietrich D  and  Kristiansen G  (2016) PD‐L1 promoter methylation is a prognostic biomarker for biochemical recurrence‐free survival in prostate cancer patients following radical prostatectomy. Oncotarget 7, 79943–79955.27835597 </plain></SENT>
</text></ref><ref id="feb412568-bib-0021"><text><SENT sid="175" pm="."><plain>21  Goltz D ,  Gevensleben H ,  Dietrich J  and  Dietrich D  (2017) PD‐L1 (CD274) promoter methylation predicts survival in colorectal cancer patients. Oncoimmunology 6, e1257454.28197377 </plain></SENT>
</text></ref><ref id="feb412568-bib-0022"><text><SENT sid="176" pm="."><plain>22  Goltz D ,  Gevensleben H ,  Grünen S ,  Dietrich J ,  Kristiansen G ,  Landsberg J  and  Dietrich D  (2017) PD‐L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia. Leukemia 31, 738–743.27840427 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
